Hinge Bio’s GEM-DIMER™ technology is broadly applicable to all antibody-based therapeutics and antibody-based cellular therapies that would benefit from the ability to engage multiple targets inter- as well as intracellularly and with high affinity. This novel platform has already yielded pre-clinical product candidates to address the problems of resistance, inadequate efficacy and side effects in the fields of cancer, inflammatory disease and infectious disease.

Hinge Bio’s initial focus is applying its GEM-DIMER™ technology to design and develop cancer therapeutics with greater functionality relative to existing products. To date, antibody technologies are typically limited in the number and types of domains that can be mobilized. In contrast, a single multivalent, multispecific GEM-DIMER™ molecule may improve the therapeutic benefit by incorporating antibody and/or other protein domains that direct tumor targeting, T/NK/macrophage effector cell engagement and effector cell activation, as well as domains to localize activity to the tumor microenvironment.

Hinge Bio’s inflammatory disease strategy leverages the unique advantages of its technology to combine multiple existing antibodies and/or other protein drugs into single molecules with enhanced functionality. These novel interpretations of validated therapeutics are intended to grow markets with enhanced efficacy, the ability to address non-responders, and greater cost effectiveness.

In infectious disease, Hinge Bio’s GEM-DIMER™ therapeutic candidate, COVICEPT™, represents an entirely new approach to the treatment and prevention of COVID-19 infection. By including the host cell surface SARS-binding receptor, ACE2, in a GEM-DIMER™ as a decoy to trap the virus, neutralization of all major SARS-CoV-2 viral variants has been demonstrated preclinically. In contrast to the previously approved antibody therapeutics that target the viral spike proteins, COVICEPT™ is expected to retain its efficacy in spite of future evolution of the virus.